Automate Your Wheel Strategy on DXCM
With Tiblio's Option Bot, you can configure your own wheel strategy including DXCM - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol DXCM
- Rev/Share 10.9686
- Book/Share 6.5624
- PB 12.3782
- Debt/Equity 1.0024
- CurrentRatio 1.5203
- ROIC 0.0954
- MktCap 31854789865.0
- FreeCF/Share 1.4558
- PFCF 55.8073
- PE 55.7311
- Debt/Assets 0.352
- DivYield 0
- ROE 0.2562
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | DXCM | Truist | -- | Buy | -- | $102 | June 16, 2025 |
| Initiation | DXCM | Goldman | -- | Buy | -- | $104 | May 30, 2025 |
| Initiation | DXCM | Mizuho | -- | Outperform | -- | $85 | April 10, 2025 |
| Upgrade | DXCM | Redburn Atlantic | Neutral | Buy | $85 | $115 | Feb. 3, 2025 |
| Upgrade | DXCM | Robert W. Baird | Neutral | Outperform | $86 | $104 | Jan. 16, 2025 |
News
Dexcom's Arizona facility can service good portion of U.S. business, says CEO
Published: August 05, 2025 by: CNBC Television
Sentiment: Positive
CNBC's "The Exchange" team discusses the potential of tariffs on pharmaceuticals, U.S. manufacturing and more with Dexcom CEO and chairman Kevin Sayer.
Read More
DexCom Stock Falls Despite Q2 Earnings Beat & 2025 Sales View Raise
Published: July 31, 2025 by: Zacks Investment Research
Sentiment: Positive
DXCM beats on Q2 earnings and raises 2025 sales guidance, but shares dip as margin pressure dampens investor enthusiasm.
Read More
Will DXCM Q2 Earnings Reflect U.S. Coverage Expansion & Stelo Impact?
Published: July 24, 2025 by: Zacks Investment Research
Sentiment: Positive
DexCom Q2 results are likely to reflect strong growth on the back of coverage by two large PBMs and Stelo traction, driving momentum and market expansion in 2025.
Read More
DexCom: Delivering Consistent Growth
Published: July 21, 2025 by: Seeking Alpha
Sentiment: Positive
DexCom focuses on continuous glucose monitoring systems, with a strong market position and global reach. Q1 results showed 13% revenue growth, beating expectations, though earnings were slightly below consensus. Analysts remain bullish, with most issuing Buy ratings and price targets ranging from $87 to $110 per share.
Read More
Are Medical Stocks Lagging DexCom (DXCM) This Year?
Published: July 21, 2025 by: Zacks Investment Research
Sentiment: Negative
Here is how DexCom (DXCM) and Amarin (AMRN) have performed compared to their sector so far this year.
Read More
Why This Beaten-Down Medical Device Stock Could Be Your Best Investment for the Next 5 Years
Published: July 20, 2025 by: The Motley Fool
Sentiment: Negative
Medical device specialist DexCom (DXCM -0.33%) has encountered significant headwinds in the past year. The company's financial results haven't been quite up to the market's standards, and broader market volatility caused by President Donald Trump's trade policies isn't helping either.
Read More
Dexcom Unveils Season 4 Roster for Game-Changing NIL Program at Signing Day Camp Hosted by Mark Andrews
Published: July 17, 2025 by: Business Wire
Sentiment: Neutral
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today the launch of the fourth season of Dexcom U, the company's one-of-a-kind NIL (Name, Image and Likeness) program exclusively for college athletes with diabetes. This year's Dexcom U roster welcomes 13 new athletes from colleges and universities across the country — including the University of Oregon, San Diego State University, and Northwestern University — representing 12 sports suc.
Read More
DexCom (DXCM) Upgraded to Strong Buy: Here's What You Should Know
Published: July 14, 2025 by: Zacks Investment Research
Sentiment: Positive
DexCom (DXCM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Read More
Is DexCom (DXCM) Stock Outpacing Its Medical Peers This Year?
Published: July 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Here is how DexCom (DXCM) and Bayer Aktiengesellschaft (BAYRY) have performed compared to their sector so far this year.
Read More
3 Reasons Growth Investors Will Love DexCom (DXCM)
Published: July 02, 2025 by: Zacks Investment Research
Sentiment: Positive
DexCom (DXCM) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Read More
Here's Why DexCom (DXCM) is a Strong Momentum Stock
Published: June 27, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Why DexCom (DXCM) is a Top Growth Stock for the Long-Term
Published: June 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Johnson Fistel has Commenced an Investigation on Behalf of DexCom, Inc. Shareholders
Published: June 05, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, June 05, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP, a leading stockholder rights law firm, has initiated an investigation into the board members and executive officers of DexCom, Inc. (NASDAQ: DXCM) for potential breaches of fiduciary duties and violations of the federal securities laws.
Read More
Profit From the Silver Tsunami: Must-Watch Senior Care & Aging Stocks
Published: June 04, 2025 by: Zacks Investment Research
Sentiment: Positive
BSX, ABBV, AMGN and DXCM are tapping into the aging boom with cutting-edge tech, chronic care drugs and senior-focused innovations.
Read More
Here's Why You Should Add DexCom Stock to Your Portfolio Now
Published: May 16, 2025 by: Zacks Investment Research
Sentiment: Positive
DXCM continues to raise investor optimism due to its strong product portfolio.
Read More
5 High-Flying Medical Instrument Stocks to Buy Despite Recent Turmoil
Published: May 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Five high-flying medical instrument stocks are: DXCM, IDXX, NPCE, CLPT, FMS.
Read More
Top Health & Fitness Stocks to Buy for the Wellness Boom
Published: May 14, 2025 by: Zacks Investment Research
Sentiment: Positive
The health and fitness boom is fueling demand for gyms, nutrition, and wellness services. Stocks like SFM, HIMS and DXCM are well-positioned to benefit.
Read More
All You Need to Know About DexCom (DXCM) Rating Upgrade to Buy
Published: May 12, 2025 by: Zacks Investment Research
Sentiment: Positive
DexCom (DXCM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
Buy 5 Health and Fitness Stocks to Enhance Your Portfolio Returns
Published: May 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Five Health and Fitness stocks to buy now are: SFM, DXCM, HIMS, UNFI, GDRX.
Read More
DexCom Q1 Earnings: Organic Revenue Growth Versus Cost Pressure
Published: May 09, 2025 by: Seeking Alpha
Sentiment: Neutral
DexCom's Q1 2025 earnings show strong growth potential, but cost pressures are impacting margins, leading me to lower my rating from buy to hold. Despite demographic tailwinds and a growing market, gross margin declines and cost pressures present significant downside risks. My updated DCF analysis yields a price target of $92.90 for DXCM stock, only a 9% upside from current prices, reducing the margin of safety.
Read More
DexCom Stock: Earnings Beat and New Market Access Drive Bull Case
Published: May 08, 2025 by: MarketBeat
Sentiment: Positive
DexCom, Inc. NASDAQ: DXCM has once again demonstrated its formidable position in the continuous glucose monitoring (CGM) market, delivering outstanding first-quarter 2025 financial results that underscore its sustained momentum. The company's performance, driven by strong product demand, successful innovation, and strategic market access expansion, strongly supports an ambitious trajectory for the remainder of 2025, indicating a clear path towards further solidifying its leadership in diabetes technology.
Read More
5 Best Stocks of the S&P 500 ETF in the Past Month
Published: May 05, 2025 by: Zacks Investment Research
Sentiment: Positive
The S&P 500 is enjoying its longest winning streak since 2004. We have highlighted the five best stocks in the S&P 500 over the past month.
Read More
DexCom Stock Rises Despite Q1 Earnings Miss & Lower Margins
Published: May 02, 2025 by: Zacks Investment Research
Sentiment: Positive
DXCM's first-quarter 2025 earnings decline despite increasing sales. Its performance in 2025 is expected to be fueled by global growth in CGM adoption, strong Sensor sales and expansion into new markets.
Read More
Nasdaq Index: Dexcom, Meta, ON Semi Lead US Stocks Rebound on Trade Optimism
Published: May 02, 2025 by: FXEmpire
Sentiment: Positive
Nasdaq jumps as Dexcom, Palantir, and ON Semi soar. Jobs report beats forecasts, easing inflation fears and driving US stock market optimism.
Read More
Dexcom Stock Is Today's Big Winner After Earnings. Why the Medtech Is Soaring.
Published: May 02, 2025 by: Barrons
Sentiment: Positive
Dexcom, the maker of glucose monitors for patients with diabetes, reports a strong first quarter.
Read More
MedTech Stocks' Earnings to Watch on May 1: BDX, CAH, BAX, DXCM & SYK
Published: April 30, 2025 by: Zacks Investment Research
Sentiment: Positive
This earnings season so far has reflected a continued recovery in sales for companies within the Medical sector. Earnings have increased year over year, albeit at a slower pace than revenues.
Read More
DexCom Shares May Rise as G7 15-Day CGM System Gets FDA Clearance
Published: April 11, 2025 by: Zacks Investment Research
Sentiment: Positive
DXCM secures FDA clearance for its G7 15-Day CGM, the longest-lasting and most accurate wearable, enhancing user convenience and expanding diabetes care access.
Read More
FDA Approves Dexcom's 15-Day Wearable Glucose Management System. Company Plans US Launch
Published: April 10, 2025 by: Benzinga
Sentiment: Positive
The U.S. Food and Drug Administration approved DexCom, Inc.'s DXCM Dexcom G7 15-Day Continuous Glucose Monitoring System for people over 18 with diabetes.
Read More
DexCom Stock Rises as Glucose Monitoring System Gets FDA Clearance
Published: April 10, 2025 by: Barrons
Sentiment: Positive
DexCom says its G7 15 Day system will land on the market in the second half of 2025.
Read More
Nanowear Announces Continuous Glucose Monitoring (CGM) Licensing and Data Partnership With Dexcom
Published: March 25, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)--Nanowear, a leader in home-based cardiometabolic digital diagnostics announced that SimpleSense™, a nanotechnology-enabled wearable, mobile and software diagnostics platform, will ingest glucose data from Dexcom G7 Continuous Glucose Monitoring Systems (CGM) time synchronously alongside Nanowear's previously FDA cleared cardiovascular biomarkers. The continuous combination of glucose readings, blood pressure, ECGs, lung volume, respiration and hemodynamics offer unpre.
Read More
About DexCom, Inc. (DXCM)
- IPO Date 2005-04-14
- Website https://www.dexcom.com
- Industry Medical - Devices
- CEO Kevin Ronald Sayer
- Employees 10200